Janssen's Zytiga fails to impress NICE
This article was originally published in Scrip
Executive Summary
Janssen Cilag has failed to convince NICE, the health technology appraisal institute for England and Wales, that its oral prostate cancer drug Zytiga (abiraterone), provides enough benefit to justify the cost. Today's draft recommendations come despite the offer of a patient access scheme and NICE's acknowledgement that the drug does prolong life.
You may also be interested in...
Lack Of Industry Involvement In EU HTA Scoping Process Exacerbates ‘Unworkable’ Timelines
Scientific advice could help companies make up for the lack of involvement in scoping, but slots are in short supply.
German HTA Queries Polivy Benefits Amid Lack Of Evidence
Roche’s lymphoma drug Polivy could face pricing challenges in Germany as it undergoes a full benefit assessment.
Germany Confirms No Reimbursement Status For ‘Lifestyle’ Drug Wegovy
In Germany Novo Nordisk’s obesity drug Wegovy will remain excluded from reimbursement for obesity, unlike Rhythm’s Imcivree.